David H Gutmann

List of Publications by Citations

501 papers	34,724 citations	91 h-index	167 g-index
530 ext. papers	40,166 ext. citations	7.7 avg, IF	7.33 L-index

#	Paper	IF	Citations
501	The somatic genomic landscape of glioblastoma. *Cell*, **2013**, 155, 462-77	56.2	2900
500	Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. *Cell*, **2016**, 164, 550-63	56.2	1140
499	Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. *Nature Neuroscience*, **2008**, 11, 251-3	25.5	843
498	The Diagnostic Evaluation and Multidisciplinary Management of Neurofibromatosis 1 and Neurofibromatosis 2. *JAMA - Journal of the American Medical Association*, **1997**, 278, 51	27.4	780
497	The role of microglia and macrophages in glioma maintenance and progression. *Nature Neuroscience*, **2016**, 19, 20-7	25.5	743
496	Subtypes of medulloblastoma have distinct developmental origins. *Nature*, **2010**, 468, 1095-9	50.4	590
495	Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. *Nature*, **1992**, 356, 713-5	50.4	589
494	Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. *Annals of Neurology*, **2008**, 63, 444-53	9.4	494
493	Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. *Cell*, **2017**, 171, 950-965.e28	56.2	451
492	Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations. *Annals of Neurology*, **2007**, 61, 189-98	9.4	448
491	Neurofibromatosis type 1 revisited. *Pediatrics*, **2009**, 123, 124-33	7.4	439
490	The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. *Genes and Development*, **2001**, 15, 968-80	12.6	389
489	International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. *Cancer Research*, **2002**, 62, 1573-7	10.1	376
488	Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Glioma Task Force. *Annals of Neurology*, **1997**, 41, 143-9	9.4	374
487	cDNA cloning of the type 1 neurofibromatosis gene: complete sequence of the NF1 gene product. *Genomics*, **1991**, 11, 931-40	4.3	350
486	Neurofibromin regulation of ERK signaling modulates GABA release and learning. *Cell*, **2008**, 135, 549-60	56.2	311
485	The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. *JAMA - Journal of the American Medical Association*, **1997**, 278, 51-7	27.4	310

484	Neurofibromatosis type 1. *Nature Reviews Disease Primers*, **2017**, 3, 17004	51.1	299
483	Astrocyte-specific TSC1 conditional knockout mice exhibit abnormal neuronal organization and seizures. *Annals of Neurology*, **2002**, 52, 285-96	9.4	292
482	Neurofibromatosis type 1: a multidisciplinary approach to care. *Lancet Neurology, The*, **2014**, 13, 834-43	24.1	285
481	Challenges to curing primary brain tumours. *Nature Reviews Clinical Oncology*, **2019**, 16, 509-520	19.4	284
480	Cellular and Molecular Identity of Tumor-Associated Macrophages in Glioblastoma. *Cancer Research* , **2017**, 77, 2266-2278	10.1	282
479	Cardiovascular disease in neurofibromatosis 1: report of the NF1 Cardiovascular Task Force. *Genetics in Medicine*, **2002**, 4, 105-11	8.1	276
478	Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors. *Cancer Research*, **2005**, 65, 2755-60	10.1	242
477	Astrocyte-specific inactivation of the neurofibromatosis 1 gene (NF1) is insufficient for astrocytoma formation. *Molecular and Cellular Biology*, **2002**, 22, 5100-13	4.8	242
476	Identification of the neurofibromatosis type 1 gene product. *Proceedings of the National Academy of Sciences of the United States of America*, **1991**, 88, 9658-62	11.5	225
475	Molecular pathogenesis of meningiomas. *Journal of Neuro-Oncology*, **2004**, 70, 183-202	4.8	220
474	Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. *Cancer Research*, **2010**, 70, 512-9	10.1	201
473	Interdomain binding mediates tumor growth suppression by the NF2 gene product. *Oncogene*, **1997**, 15, 2505-9	9.2	199
472	Optic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity. *Cancer Research*, **2003**, 63, 8573-7	10.1	199
471	Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis. *Neuro-Oncology*, **2012**, 14, 790-7	1	192
470	Pten loss causes hypertrophy and increased proliferation of astrocytes in vivo. *Cancer Research*, **2004**, 64, 7773-9	10.1	182
469	Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma. *Cancer Research*, **2005**, 65, 7121-6	10.1	174
468	Large-scale molecular comparison of human schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues. *Cancer Research*, **2006**, 66, 2584-91	10.1	171
467	Differential effects of cAMP in neurons and astrocytes. Role of B-raf. *Journal of Biological Chemistry* , **1999**, 274, 25842-8	5.4	167

466	Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse. *Genes and Development*, **2002**, 16, 1060-5	12.6	166
465	Impaired glial glutamate transport in a mouse tuberous sclerosis epilepsy model. *Annals of Neurology*, **2003**, 54, 251-6	9.4	162
464	Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex. *Human Molecular Genetics*, **2011**, 20, 445-54	5.6	161
463	Neurofibromatosis-1 regulates neuronal and glial cell differentiation from neuroglial progenitors in vivo by both cAMP- and Ras-dependent mechanisms. *Cell Stem Cell*, **2007**, 1, 443-57	18	159
462	Aggressive phenotypic and genotypic features in pediatric and NF2-associated meningiomas: a clinicopathologic study of 53 cases. *Journal of Neuropathology and Experimental Neurology*, **2001**, 60, 994-1003	3.1	156
461	Malignant peripheral nerve sheath tumors in neurofibromatosis 1. *American Journal of Medical Genetics Part A*, **2000**, 93, 388-392		156
460	Protein 4.1 tumor suppressors: getting a FERM grip on growth regulation. *Journal of Cell Science*, **2002**, 115, 3991-4000	5.3	149
459	Distinct genetic signatures among pilocytic astrocytomas relate to their brain region origin. *Cancer Research*, **2007**, 67, 890-900	10.1	148
458	Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation. *Development (Cambridge)*, **2005**, 132, 5577-88	6.6	145
457	Loss of DAL-1, a protein 4.1-related tumor suppressor, is an important early event in the pathogenesis of meningiomas. *Human Molecular Genetics*, **2000**, 9, 1495-500	5.6	144
456	Neurofibromatosis-1 (Nf1) heterozygous brain microglia elaborate paracrine factors that promote Nf1-deficient astrocyte and glioma growth. *Human Molecular Genetics*, **2007**, 16, 1098-112	5.6	143
455	Nectin-like proteins mediate axon Schwann cell interactions along the internode and are essential for myelination. *Journal of Cell Biology*, **2007**, 178, 861-74	7.3	141
454	Gliomas in neurofibromatosis type 1: a clinicopathologic study of 100 patients. *Journal of Neuropathology and Experimental Neurology*, **2008**, 67, 240-9	3.1	137
453	The neurofibromatosis type 1 gene and its protein product, neurofibromin. *Neuron*, **1993**, 10, 335-43	13.9	136
452	Loss of merlin expression in sporadic meningiomas, ependymomas and schwannomas. *Neurology*, **1997**, 49, 267-70	6.5	133
451	Mutations in the neurofibromatosis 1 gene in sporadic malignant melanoma cell lines. *Nature Genetics*, **1993**, 3, 118-21	36.3	133
450	Merlin, DAL-1, and progesterone receptor expression in clinicopathologic subsets of meningioma: a correlative immunohistochemical study of 175 cases. *Journal of Neuropathology and Experimental Neurology*, **2000**, 59, 872-9	3.1	132
449	Merlin differentially associates with the microtubule and actin cytoskeleton. *Journal of Neuroscience Research*, **1998**, 51, 403-15	4.4	126

448	Astrocyte loss of mutant SOD1 delays ALS disease onset and progression in G85R transgenic mice. *Human Molecular Genetics*, **2011**, 20, 286-93	5.6	125
447	Intracranial gliomas in neurofibromatosis type 1. *American Journal of Medical Genetics Part A*, **1999**, 89, 38-44		124
446	Gliomas presenting after age 10 in individuals with neurofibromatosis type 1 (NF1). *Neurology*, **2002**, 59, 759-61	6.5	123
445	The neurofibromatosis 1 gene product neurofibromin regulates pituitary adenylate cyclase-activating polypeptide-mediated signaling in astrocytes. *Journal of Neuroscience*, **2003**, 23, 8949-54	6.6	122
444	Preclinical cancer therapy in a mouse model of neurofibromatosis-1 optic glioma. *Cancer Research*, **2008**, 68, 1520-8	10.1	120
443	BRAF(V600E) mutation is a negative prognosticator in pediatric ganglioglioma. *Acta Neuropathologica*, **2013**, 125, 901-10	14.3	119
442	Optic pathway gliomas in neurofibromatosis type 1: the effect of presenting symptoms on outcome. *American Journal of Medical Genetics Part A*, **2003**, 122A, 95-9		118
441	Loss of neurofibromatosis 1 (NF1) gene expression in NF1-associated pilocytic astrocytomas. *Neuropathology and Applied Neurobiology*, **2000**, 26, 361-7	5.2	118
440	Expression of ICAM-1, TNF-alpha, NF kappa B, and MAP kinase in tubers of the tuberous sclerosis complex. *Neurobiology of Disease*, **2003**, 14, 279-90	7.5	116
439	Loss of neurofibromin is associated with activation of RAS/MAPK and PI3-K/AKT signaling in a neurofibromatosis 1 astrocytoma. *Journal of Neuropathology and Experimental Neurology*, **2000**, 59, 759-67	3.1	115
438	Neurofibromatosis type 1 (NF1): diagnosis and management. *Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn*, **2013**, 115, 939-55	3	112
437	Astrocyte gp130 expression is critical for the control of Toxoplasma encephalitis. *Journal of Immunology*, **2008**, 181, 2683-93	5.3	111
436	NF1 deletions in S-100 protein-positive and negative cells of sporadic and neurofibromatosis 1 (NF1)-associated plexiform neurofibromas and malignant peripheral nerve sheath tumors. *American Journal of Pathology*, **2001**, 159, 57-61	5.8	110
435	Neurofibromatosis 2 (NF2) tumor suppressor merlin inhibits phosphatidylinositol 3-kinase through binding to PIKE-L. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 18200-5	11.5	109
434	The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP. *Neoplasia*, **2008**, 10, 1204-12	6.4	108
433	Neurofibromin regulates neural stem cell proliferation, survival, and astroglial differentiation in vitro and in vivo. *Journal of Neuroscience*, **2005**, 25, 5584-94	6.6	106
432	Neurofibromatosis type 1 gene product (neurofibromin) associates with microtubules. *Somatic Cell and Molecular Genetics*, **1993**, 19, 265-74		106
431	Astrocyte-derived vascular endothelial growth factor stabilizes vessels in the developing retinal vasculature. *PLoS ONE*, **2010**, 5, e11863	3.7	104

430	Integrin-dependent and -independent functions of astrocytic fibronectin in retinal angiogenesis. *Development (Cambridge)*, **2011**, 138, 4451-63	6.6	103
429	Identification of a progenitor cell of origin capable of generating diverse meningioma histological subtypes. *Oncogene*, **2011**, 30, 2333-44	9.2	102
428	Abnormal glutamate homeostasis and impaired synaptic plasticity and learning in a mouse model of tuberous sclerosis complex. *Neurobiology of Disease*, **2007**, 28, 184-96	7.5	101
427	Haploinsufficiency for the neurofibromatosis 1 (NF1) tumor suppressor results in increased astrocyte proliferation. *Oncogene*, **1999**, 18, 4450-9	9.2	101
426	Oligodendroglial myelination requires astrocyte-derived lipids. *PLoS Biology*, **2017**, 15, e1002605	9.7	101
425	Clinic-based study of plexiform neurofibromas in neurofibromatosis 1. *American Journal of Medical Genetics Part A*, **2000**, 92, 132-135		100
424	Reduced striatal dopamine underlies the attention system dysfunction in neurofibromatosis-1 mutant mice. *Human Molecular Genetics*, **2010**, 19, 4515-28	5.6	99
423	Recent advances in neurofibromatosis type 1. *Current Opinion in Neurology*, **2004**, 17, 101-5	7.1	99
422	Morphologic and immunohistochemical features of malignant peripheral nerve sheath tumors and cellular schwannomas. *Modern Pathology*, **2015**, 28, 187-200	9.8	97
421	Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation. *Glia*, **2009**, 57, 1239-49	9	97
420	Epileptogenesis and reduced inward rectifier potassium current in tuberous sclerosis complex-1-deficient astrocytes. *Epilepsia*, **2005**, 46, 1871-80	6.4	97
419	Microglia/Brain Macrophages as Central Drivers of Brain Tumor Pathobiology. *Neuron*, **2019**, 104, 442-449	13.9	96
418	Molecular characterization of human meningiomas by gene expression profiling using high-density oligonucleotide microarrays. *American Journal of Pathology*, **2002**, 161, 665-72	5.8	96
417	Immunohistochemical analysis supports a role for INI1/SMARCB1 in hereditary forms of schwannomas, but not in solitary, sporadic schwannomas. *Brain Pathology*, **2008**, 18, 517-9	6	95
416	Serine 518 phosphorylation modulates merlin intramolecular association and binding to critical effectors important for NF2 growth suppression. *Oncogene*, **2004**, 23, 8447-54	9.2	95
415	Differential NF1, p16, and EGFR patterns by interphase cytogenetics (FISH) in malignant peripheral nerve sheath tumor (MPNST) and morphologically similar spindle cell neoplasms. *Journal of Neuropathology and Experimental Neurology*, **2002**, 61, 702-9	3.1	95
414	Oligodendrogliomas result from the expression of an activated mutant epidermal growth factor receptor in a RAS transgenic mouse astrocytoma model. *Cancer Research*, **2003**, 63, 1106-13	10.1	95
413	Neurofibromatosis 2. *Current Opinion in Neurology*, **2003**, 16, 27-33	7.1	93

412	Spatiotemporal differences in CXCL12 expression and cyclic AMP underlie the unique pattern of optic glioma growth in neurofibromatosis type 1. *Cancer Research*, **2007**, 67, 8588-95	10.1	92
411	Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study. *Neuro-Oncology*, **2015**, 17, 596-603	1	91
410	High-grade glioma formation results from postnatal pten loss or mutant epidermal growth factor receptor expression in a transgenic mouse glioma model. *Cancer Research*, **2006**, 66, 7429-37	10.1	91
409	Regulated temporal-spatial astrocyte precursor cell proliferation involves BRAF signalling in mammalian spinal cord. *Development (Cambridge)*, **2012**, 139, 2477-87	6.6	90
408	Neurofibromatosis-1 heterozygosity increases microglia in a spatially and temporally restricted pattern relevant to mouse optic glioma formation and growth. *Journal of Neuropathology and Experimental Neurology*, **2011**, 70, 51-62	3.1	89
407	Neurofibromatosis-1 regulates neuroglial progenitor proliferation and glial differentiation in a brain region-specific manner. *Genes and Development*, **2010**, 24, 2317-29	12.6	89
406	DAL-1/4.1B tumor suppressor interacts with protein arginine N-methyltransferase 3 (PRMT3) and inhibits its ability to methylate substrates in vitro and in vivo. *Oncogene*, **2004**, 23, 7761-71	9.2	89
405	Increased expression of the NF2 tumor suppressor gene product, merlin, impairs cell motility, adhesionand spreading. *Human Molecular Genetics*, **1999**, 8, 267-75	5.6	89
404	Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1. *Annals of Neurology*, **2014**, 75, 309-16	9.4	88
403	Array-based comparative genomic hybridization identifies CDK4 and FOXM1 alterations as independent predictors of survival in malignant peripheral nerve sheath tumor. *Clinical Cancer Research*, **2011**, 17, 1924-34	12.9	88
402	Identification of dominant negative mutants of Rheb GTPase and their use to implicate the involvement of human Rheb in the activation of p70S6K. *Journal of Biological Chemistry*, **2003**, 278, 39921-30	5.4	87
401	Neurofibromatosis 1. *Neurologic Clinics*, **2002**, 20, 841-65	4.5	87
400	Defective cAMP generation underlies the sensitivity of CNS neurons to neurofibromatosis-1 heterozygosity. *Journal of Neuroscience*, **2010**, 30, 5579-89	6.6	85
399	Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1. *Cancer Research*, **2010**, 70, 5717-27	10.1	85
398	Merlin is a potent inhibitor of glioma growth. *Cancer Research*, **2008**, 68, 5733-42	10.1	84
397	Neurofibromatosis 1: closing the GAP between mice and men. *Current Opinion in Genetics and Development*, **2003**, 13, 20-7	4.9	84
396	Increased c-Jun-NH2-kinase signaling in neurofibromatosis-1 heterozygous microglia drives microglia activation and promotes optic glioma proliferation. *Cancer Research*, **2008**, 68, 10358-66	10.1	83
395	Functional outcome measures for NF1-associated optic pathway glioma clinical trials. *Neurology*, **2013**, 81, S15-24	6.5	82

394	High-resolution, dual-platform aCGH analysis reveals frequent HIPK2 amplification and increased expression in pilocytic astrocytomas. *Oncogene*, **2008**, 27, 4745-51	9.2	82
393	Innate neural stem cell heterogeneity determines the patterning of glioma formation in children. *Cancer Cell*, **2012**, 22, 131-8	24.3	80
392	The neurofibromatoses: when less is more. *Human Molecular Genetics*, **2001**, 10, 747-55	5.6	80
391	Glioma formation in neurofibromatosis 1 reflects preferential activation of K-RAS in astrocytes. *Cancer Research*, **2005**, 65, 236-45	10.1	80
390	The adhesion GPCR Gpr56 regulates oligodendrocyte development via interactions with G12/13 and RhoA. *Nature Communications*, **2015**, 6, 6122	17.4	79
389	Expression of the neurofibromatosis I gene product, neurofibromin, in blood vessel endothelial cells and smooth muscle. *Neurobiology of Disease*, **1995**, 2, 13-21	7.5	79
388	Effect of merlin phosphorylation on neurofibromatosis 2 (NF2) gene function. *Oncogene*, **2004**, 23, 580-7	9.2	78
387	NFB-09. ENROLLMENT AND CLINICAL CHARACTERISTICS OF NEWLY DIAGNOSED, NEUROFIBROMATOSIS TYPE 1 ASSOCIATED OPTIC PATHWAY GLIOMA (NF1-OPG): PRELIMINARY RESULTS FROM AN INTERNATIONAL MULTI-CENTER NATURAL HISTORY STUDY. *Neuro-Oncology*,	1	78
386	LGG-06. COMPREHENSIVE GENOMIC CHARACTERIZATION AND INTEGRATED CLINICAL ANALYSIS OF LOW-GRADE GLIOMAS IN CHILDREN WITH NEUROFIBROMATOSIS TYPE 1. *Neuro-Oncology*, **2021**, 23, i32-i32	1	78
385	Optic Pathway Gliomas in Neurofibromatosis Type 1. *Journal of Child Neurology*, **2018**, 33, 73-81	2.5	77
384	Somatic neurofibromatosis type 1 (NF1) inactivation characterizes NF1-associated pilocytic astrocytoma. *Genome Research*, **2013**, 23, 431-9	9.7	77
383	Mixed-lineage kinase 3 regulates B-Raf through maintenance of the B-Raf/Raf-1 complex and inhibition by the NF2 tumor suppressor protein. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 4463-8	11.5	77
382	Neurofibromatosis 1: from lab bench to clinic. *Pediatric Neurology*, **2005**, 32, 221-8	2.9	76
381	Molecular analysis of astrocytomas presenting after age 10 in individuals with NF1. *Neurology*, **2003**, 61, 1397-400	6.5	76
380	Comprehensive gene expression meta-analysis identifies signature genes that distinguish microglia from peripheral monocytes/macrophages in health and glioma. *Acta Neuropathologica Communications*, **2019**, 7, 20	7.3	75
379	Neurofibromatosis type 1. *Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn*, **2015**, 132, 75-86	3	75
378	Reduced microglial CX3CR1 expression delays neurofibromatosis-1 glioma formation. *Annals of Neurology*, **2013**, 73, 303-8	9.4	75
377	Neurofibromatosis-1 regulates mTOR-mediated astrocyte growth and glioma formation in a TSC/Rheb-independent manner. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 15996-6001	11.5	73

376	Frequent promoter hypermethylation and transcriptional downregulation of the NDRG2 gene at 14q11.2 in primary glioblastoma. *International Journal of Cancer*, **2008**, 123, 2080-6	7.5	73
375	T-cadherin-mediated cell growth regulation involves G2 phase arrest and requires p21(CIP1/WAF1) expression. *Molecular and Cellular Biology*, **2003**, 23, 566-78	4.8	73
374	Neurofibromatosis type 1 - a model for nervous system tumour formation?. *Nature Reviews Cancer*, **2005**, 5, 557-64	31.3	72
373	Expression of the neurofibromatosis 2 tumor suppressor gene product, merlin, in Schwann cells. *Journal of Neuroscience Research*, **1996**, 46, 595-605	4.4	71
372	Deconvoluting mTOR biology. *Cell Cycle*, **2012**, 11, 236-48	4.7	70
371	BRAF-V600E mutation in pediatric and adult glioblastoma. *Neuro-Oncology*, **2014**, 16, 318-9	1	69
370	Modeling cognitive dysfunction in neurofibromatosis-1. *Trends in Neurosciences*, **2013**, 36, 237-47	13.3	69
369	Identification of a third Protein 4.1 tumor suppressor, Protein 4.1R, in meningioma pathogenesis. *Neurobiology of Disease*, **2003**, 13, 191-202	7.5	69
368	RAS pathway activation and an oncogenic RAS mutation in sporadic pilocytic astrocytoma. *Neurology*, **2005**, 65, 1335-6	6.5	69
367	Ezrin, radixin, and moesin are components of Schwann cell microvilli. *Journal of Neuroscience Research*, **2001**, 65, 150-64	4.4	69
366	Akt phosphorylation regulates the tumour-suppressor merlin through ubiquitination and degradation. *Nature Cell Biology*, **2007**, 9, 1199-207	23.4	68
365	Promoter hypermethylation of the potential tumor suppressor DAL-1/4.1B gene in renal clear cell carcinoma. *International Journal of Cancer*, **2006**, 118, 916-23	7.5	68
364	An alternatively-spliced mRNA in the carboxy terminus of the neurofibromatosis type 1 (NF1) gene is expressed in muscle. *Human Molecular Genetics*, **1993**, 2, 989-92	5.6	68
363	Roadmap for the Emerging Field of Cancer Neuroscience. *Cell*, **2020**, 181, 219-222	56.2	68
362	Optic Pathway Gliomas in Neurofibromatosis Type 1: An Update: Surveillance, Treatment Indications, and Biomarkers of Vision. *Journal of Neuro-Ophthalmology*, **2017**, 37 Suppl 1, S23-S32	2.6	67
361	Pediatric glioma-associated KIAA1549:BRAF expression regulates neuroglial cell growth in a cell type-specific and mTOR-dependent manner. *Genes and Development*, **2012**, 26, 2561-6	12.6	67
360	Meningioma: an update. *Current Opinion in Neurology*, **2004**, 17, 687-92	7.1	67
359	Neurofibromatosis type 1: modeling CNS dysfunction. *Journal of Neuroscience*, **2012**, 32, 14087-93	6.6	66

358	Predictive value of café au lait macules at initial consultation in the diagnosis of neurofibromatosis type 1. *Archives of Dermatology*, **2009**, 145, 883-7		66
357	Disease Burden and Symptom Structure of Autism in Neurofibromatosis Type 1: A Study of the International NF1-ASD Consortium Team (INFACT). *JAMA Psychiatry*, **2016**, 73, 1276-1284	14.5	65
356	Sirolimus for non-progressive NF1-associated plexiform neurofibromas: an NF clinical trials consortium phase II study. *Pediatric Blood and Cancer*, **2014**, 61, 982-6	3	65
355	Heterozygosity for the tuberous sclerosis complex (TSC) gene products results in increased astrocyte numbers and decreased p27-Kip1 expression in TSC2+/- cells. *Oncogene*, **2002**, 21, 4050-9	9.2	65
354	Loss of tuberous sclerosis complex 1 (Tsc1) expression results in increased Rheb/S6K pathway signaling important for astrocyte cell size regulation. *Glia*, **2004**, 47, 180-8	9	64
353	Advances in the treatment of neurofibromatosis-associated tumours. *Nature Reviews Clinical Oncology*, **2013**, 10, 616-24	19.4	63
352	Gene expression profiling reveals unique molecular subtypes of Neurofibromatosis Type I-associated and sporadic malignant peripheral nerve sheath tumors. *Brain Pathology*, **2004**, 14, 297-303	6	63
351	RNA Sequencing of Tumor-Associated Microglia Reveals Ccl5 as a Stromal Chemokine Critical for Neurofibromatosis-1 Glioma Growth. *Neoplasia*, **2015**, 17, 776-88	6.4	62
350	Visual acuity in children with low grade gliomas of the visual pathway: implications for patient care and clinical research. *Journal of Neuro-Oncology*, **2012**, 110, 1-7	4.8	61
349	Optimizing biologically targeted clinical trials for neurofibromatosis. *Expert Opinion on Investigational Drugs*, **2013**, 22, 443-62	5.9	61
348	Phosphorylation of neurofibromin by PKC is a possible molecular switch in EGF receptor signaling in neural cells. *Oncogene*, **2006**, 25, 735-45	9.2	61
347	Neurofibromatosis 1 (NF1) heterozygosity results in a cell-autonomous growth advantage for astrocytes. *Glia*, **2001**, 33, 314-23	9	61
346	The protein 4.1 tumor suppressor, DAL-1, impairs cell motility, but regulates proliferation in a cell-type-specific fashion. *Neurobiology of Disease*, **2001**, 8, 266-78	7.5	61
345	Defects in neurofibromatosis 2 protein function can arise at multiple levels. *Human Molecular Genetics*, **1998**, 7, 335-45	5.6	61
344	Neurofibromatosis type 1: piecing the puzzle together. *Canadian Journal of Neurological Sciences*, **1998**, 25, 181-91	1	61
343	Comparative gene expression profile analysis of neurofibromatosis 1-associated and sporadic pilocytic astrocytomas. *Cancer Research*, **2002**, 62, 2085-91	10.1	60
342	Nucleophosmin mediates mammalian target of rapamycin-dependent actin cytoskeleton dynamics and proliferation in neurofibromin-deficient astrocytes. *Cancer Research*, **2007**, 67, 4790-9	10.1	58
341	Natural history of neurofibromatosis 1-associated optic nerve glioma in mice. *Annals of Neurology*, **2005**, 57, 119-27	9.4	58

340	Tumorigenesis in neurofibromatosis: new insights and potential therapies. *Trends in Molecular Medicine*, **2001**, 7, 157-62	11.5	58
339	The molecular and cell biology of pediatric low-grade gliomas. *Oncogene*, **2014**, 33, 2019-26	9.2	57
338	The neurofibromatosis type 1 tumor suppressor controls cell growth by regulating signal transducer and activator of transcription-3 activity in vitro and in vivo. *Cancer Research*, **2010**, 70, 1356-66	10.1	57
337	Loss of neurofibromin in adrenal gland tumors from patients with neurofibromatosis type I. *Genes Chromosomes and Cancer*, **1994**, 10, 55-8	5	57
336	Akt- or MEK-mediated mTOR inhibition suppresses Nf1 optic glioma growth. *Neuro-Oncology*, **2015**, 17, 843-53	1	56
335	Histopathologic predictors of pilocytic astrocytoma event-free survival. *Acta Neuropathologica*, **2009**, 117, 657-65	14.3	56
334	Tumorigenesis in the brain: location, location, location. *Cancer Research*, **2007**, 67, 5579-82	10.1	56
333	Epilepsy in individuals with neurofibromatosis type 1. *Epilepsia*, **2013**, 54, 1810-4	6.4	55
332	Mutations in the GAP-related domain impair the ability of neurofibromin to associate with microtubules. *Brain Research*, **1997**, 759, 149-52	3.7	55
331	Elucidating the impact of neurofibromatosis-1 germline mutations on neurofibromin function and dopamine-based learning. *Human Molecular Genetics*, **2015**, 24, 3518-28	5.6	54
330	Axonal integrity in the absence of functional peroxisomes from projection neurons and astrocytes. *Glia*, **2010**, 58, 1532-43	9	54
329	Randomized placebo-controlled study of lovastatin in children with neurofibromatosis type 1. *Neurology*, **2016**, 87, 2575-2584	6.5	53
328	Suppression of microRNA-9 by mutant EGFR signaling upregulates FOXP1 to enhance glioblastoma tumorigenicity. *Cancer Research*, **2014**, 74, 1429-39	10.1	53
327	Differential involvement of protein 4.1 family members DAL-1 and NF2 in intracranial and intraspinal ependymomas. *Modern Pathology*, **2002**, 15, 526-31	9.8	53
326	Neurofibromatosis type 1. *Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn*, **2018**, 148, 799-811	3	52
325	Neurofibromatosis Type 1-Associated MPNST State of the Science: Outlining a Research Agenda for the Future. *Journal of the National Cancer Institute*, **2017**, 109,	9.7	52
324	The neurofibromatosis 2 protein, merlin, regulates glial cell growth in an ErbB2- and Src-dependent manner. *Molecular and Cellular Biology*, **2009**, 29, 1472-86	4.8	52
323	The natural history and treatment of epilepsy in a murine model of tuberous sclerosis. *Epilepsia*, **2007**, 48, 1470-6	6.4	52

322	Loss of tumor suppressor in lung cancer-1 (TSLC1) expression in meningioma correlates with increased malignancy grade and reduced patient survival. *Journal of Neuropathology and Experimental Neurology*, **2004**, 63, 1015-27	3.1	52
321	Dopamine deficiency underlies learning deficits in neurofibromatosis-1 mice. *Annals of Neurology*, **2013**, 73, 309-15	9.4	51
320	Harnessing preclinical mouse models to inform human clinical cancer trials. *Journal of Clinical Investigation*, **2006**, 116, 847-52	15.9	51
319	The neurobiology of neurooncology. *Annals of Neurology*, **2006**, 60, 3-11	9.4	50
318	Developmental regulation of a neuron-specific neurofibromatosis 1 isoform. *Annals of Neurology*, **1999**, 46, 777-82	9.4	50
317	High-fat diet ameliorates neurological deficits caused by defective astrocyte lipid metabolism. *FASEB Journal*, **2012**, 26, 4302-15	0.9	49
316	Pathological and molecular progression of astrocytomas in a GFAP:12 V-Ha-Ras mouse astrocytoma model. *American Journal of Pathology*, **2005**, 167, 859-67	5.8	49
315	Expression of two new protein isoforms of the neurofibromatosis type 1 gene product, neurofibromin, in muscle tissues. *Developmental Dynamics*, **1995**, 202, 302-11	2.9	49
314	miRNA-145 is downregulated in atypical and anaplastic meningiomas and negatively regulates motility and proliferation of meningioma cells. *Oncogene*, **2013**, 32, 4712-20	9.2	48
313	Mouse models of neurofibromatosis 1 and 2. *Neoplasia*, **2002**, 4, 279-90	6.4	48
312	Recent insights into neurofibromatosis type 1: clear genetic progress. *Archives of Neurology*, **1998**, 55, 778-80		47
311	Neuronal NF1/RAS regulation of cyclic AMP requires atypical PKC activation. *Human Molecular Genetics*, **2014**, 23, 6712-21	5.6	46
310	MicroRNA profiling in pediatric pilocytic astrocytoma reveals biologically relevant targets, including PBX3, NFIB, and METAP2. *Neuro-Oncology*, **2013**, 15, 69-82	1	46
309	Insights into meningioangiomatosis with and without meningioma: a clinicopathologic and genetic series of 24 cases with review of the literature. *Brain Pathology*, **2005**, 15, 55-65	6	46
308	Neurofibromatosis 2 (NF2) tumor suppressor schwannomin and its interacting protein HRS regulate STAT signaling. *Human Molecular Genetics*, **2002**, 11, 3179-89	5.6	46
307	Oculodentodigital dysplasia syndrome associated with abnormal cerebral white matter. *American Journal of Medical Genetics Part A*, **1991**, 41, 18-20		46
306	MicroRNA Profiling Reveals Marker of Motor Neuron Disease in ALS Models. *Journal of Neuroscience*, **2017**, 37, 5574-5586	6.6	45
305	HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1. *Molecular Psychiatry*, **2015**, 20, 1311-21	15.1	45

304	Merlin isoform 2 in neurofibromatosis type 2-associated polyneuropathy. *Nature Neuroscience*, **2013**, 16, 426-33	25.5	45
303	Loss of neurofibromatosis type I (NF1) gene expression in pheochromocytomas from patients without NF1. *Genes Chromosomes and Cancer*, **1995**, 13, 104-9	5	45
302	Tumor suppressor Tsc1 is a new Hsp90 co-chaperone that facilitates folding of kinase and non-kinase clients. *EMBO Journal*, **2017**, 36, 3650-3665	13	44
301	Neurofibromatosis-1 heterozygosity impairs CNS neuronal morphology in a cAMP/PKA/ROCK-dependent manner. *Molecular and Cellular Neurosciences*, **2012**, 49, 13-22	4.8	44
300	Diffusion-weighted and dynamic contrast-enhanced imaging as markers of clinical behavior in children with optic pathway glioma. *Pediatric Radiology*, **2008**, 38, 1293-9	2.8	44
299	Developmental origin of subependymal giant cell astrocytoma in tuberous sclerosis complex. *Neurology*, **2005**, 64, 1446-9	6.5	44
298	Heterozygosity for the neurofibromatosis 1 (NF1) tumor suppressor results in abnormalities in cell attachment, spreading and motility in astrocytes. *Human Molecular Genetics*, **2001**, 10, 3009-16	5.6	44
297	Recent progress toward understanding the molecular biology of von Recklinghausen neurofibromatosis. *Annals of Neurology*, **1992**, 31, 555-61	9.4	44
296	NF1 germline mutation differentially dictates optic glioma formation and growth in neurofibromatosis-1. *Human Molecular Genetics*, **2016**, 25, 1703-13	5.6	44
295	The cyclic AMP pathway is a sex-specific modifier of glioma risk in type I neurofibromatosis patients. *Cancer Research*, **2015**, 75, 16-21	10.1	43
294	CNS Tumors in Neurofibromatosis. *Journal of Clinical Oncology*, **2017**, 35, 2378-2385	2.2	43
293	ABCA1 influences neuroinflammation and neuronal death. *Neurobiology of Disease*, **2013**, 54, 445-55	7.5	43
292	Gliomas in patients with neurofibromatosis type 1. *Expert Review of Neurotherapeutics*, **2009**, 9, 535-9	4.3	43
291	The monolayer formation of Bergmann glial cells is regulated by Notch/RBP-J signaling. *Developmental Biology*, **2007**, 311, 238-50	3.1	43
290	Expression of a developmentally-regulated neuron-specific isoform of the neurofibromatosis 1 (NF1) gene. *Neuroscience Letters*, **1996**, 211, 85-8	3.3	43
289	Modulation of the neurofibromatosis type 1 gene product, neurofibromin, during Schwann cell differentiation. *Journal of Neuroscience Research*, **1993**, 36, 216-23	4.4	43
288	Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. *Genetics in Medicine*, **2021**, 23, 1506-1513	8.1	43
287	Functional analysis of neurofibromatosis 2 (NF2) missense mutations. *Human Molecular Genetics*, **2001**, 10, 1519-29	5.6	42

286	Expression of the neurofibromatosis 2 (NF2) gene isoforms during rat embryonic development. *Human Molecular Genetics*, **1995**, 4, 471-8	5.6	42
285	Attention skills in children with neurofibromatosis type 1. *Journal of Child Neurology*, **2013**, 28, 45-9	2.5	41
284	Alterations of protein 4.1 family members in ependymomas: a study of 84 cases. *Modern Pathology*, **2005**, 18, 991-7	9.8	40
283	Alterations in the rap1 signaling pathway are common in human gliomas. *Oncogene*, **1997**, 15, 1611-6	9.2	39
282	Expression profiling in tuberous sclerosis complex (TSC) knockout mouse astrocytes to characterize human TSC brain pathology. *Glia*, **2004**, 46, 28-40	9	39
281	Neurofibromin regulates somatic growth through the hypothalamic-pituitary axis. *Human Molecular Genetics*, **2008**, 17, 2956-66	5.6	38
280	Transcriptional repression of the Neurofibromatosis-1 tumor suppressor by the t(8;21) fusion protein. *Molecular and Cellular Biology*, **2005**, 25, 5869-79	4.8	38
279	Expression of the tuberous sclerosis complex gene products, hamartin and tuberin, in central nervous system tissues. *Acta Neuropathologica*, **2000**, 99, 223-30	14.3	38
278	A multi-institutional study of brainstem gliomas in children with neurofibromatosis type 1. *Neurology*, **2017**, 88, 1584-1589	6.5	37
277	Prevalence of Sleep Disturbances in Children With Neurofibromatosis Type 1. *Journal of Child Neurology*, **2013**, 28, 1400-1405	2.5	37
276	Identification of gene markers associated with aggressive meningioma by filtering across multiple sets of gene expression arrays. *Journal of Neuropathology and Experimental Neurology*, **2011**, 70, 1-12	3.1	37
275	Gene expression profiling of NF-1-associated and sporadic pilocytic astrocytoma identifies aldehyde dehydrogenase 1 family member L1 (ALDH1L1) as an underexpressed candidate biomarker in aggressive subtypes. *Journal of Neuropathology and Experimental Neurology*, **2008**, 67, 1194-204	3.1	37
274	Neurofibromatosis 2 tumor suppressor protein, merlin, forms two functionally important intramolecular associations **1999**, 58, 706-716		37
273	Estrogen activation of microglia underlies the sexually dimorphic differences in Nf1 optic glioma-induced retinal pathology. *Journal of Experimental Medicine*, **2017**, 214, 17-25	16.6	36
272	Optic nerve dysfunction in a mouse model of neurofibromatosis-1 optic glioma. *Journal of Neuropathology and Experimental Neurology*, **2009**, 68, 542-51	3.1	36
271	Preclinical in vivo evaluation of rapamycin in human malignant peripheral nerve sheath explant xenograft. *International Journal of Cancer*, **2010**, 126, 563-71	7.5	36
270	Molecular insights into neurofibromatosis 2. *Neurobiology of Disease*, **1997**, 3, 247-61	7.5	36
269	Reduced TSC2 RNA and protein in sporadic astrocytomas and ependymomas. *Annals of Neurology*, **1997**, 42, 230-5	9.4	36

268	Oculodentodigital dysplasia with cerebral white matter abnormalities in a two-generation family. *American Journal of Medical Genetics Part A*, **1995**, 57, 458-61		36
267	let-7 MicroRNAs Regulate Microglial Function and Suppress Glioma Growth through Toll-Like Receptor 7. *Cell Reports*, **2019**, 29, 3460-3471.e7	10.6	36
266	The mTOR signaling pathway as a treatment target for intracranial neoplasms. *Neuro-Oncology*, **2015**, 17, 189-99	1	35
265	cDNA hybrid capture improves transcriptome analysis on low-input and archived samples. *Journal of Molecular Diagnostics*, **2014**, 16, 440-51	5.1	35
264	CD44-independent hepatocyte growth factor/c-Met autocrine loop promotes malignant peripheral nerve sheath tumor cell invasion in vitro. *Glia*, **2004**, 45, 297-306	9	35
263	Merlin: hanging tumor suppression on the Rac. *Trends in Cell Biology*, **2001**, 11, 442-444	18.3	35
262	The 4.1/ezrin/radixin/moesin domain of the DAL-1/Protein 4.1B tumour suppressor interacts with 14-3-3 proteins. *Biochemical Journal*, **2002**, 365, 783-9	3.8	35
261	Genetic and genomic alterations differentially dictate low-grade glioma growth through cancer stem cell-specific chemokine recruitment of T cells and microglia. *Neuro-Oncology*, **2019**, 21, 1250-1262	1	34
260	Microglia as Dynamic Cellular Mediators of Brain Function. *Trends in Molecular Medicine*, **2019**, 25, 967-979	11.5	34
259	Differential cellular expression of neurotrophins in cortical tubers of the tuberous sclerosis complex. *American Journal of Pathology*, **2001**, 159, 1541-54	5.8	34
258	Hereditary retinal vasculopathy with cerebral white matter lesions. *American Journal of Medical Genetics Part A*, **1989**, 34, 217-20		34
257	Neurodevelopmental disorders in children with neurofibromatosis type 1. *Developmental Medicine and Child Neurology*, **2017**, 59, 1112-1116	3.3	33
256	Whole Exome Sequencing Reveals the Order of Genetic Changes during Malignant Transformation and Metastasis in a Single Patient with NF1-plexiform Neurofibroma. *Clinical Cancer Research*, **2015**, 21, 4201-11	12.9	33
255	TSC1 sets the rate of ribosome export and protein synthesis through nucleophosmin translation. *Cancer Research*, **2007**, 67, 1609-17	10.1	33
254	The generation and characterization of a cell line derived from a sporadic renal angiomyolipoma: use of telomerase to obtain stable populations of cells from benign neoplasms. *American Journal of Pathology*, **2001**, 159, 483-91	5.8	33
253	Ccl5 establishes an autocrine high-grade glioma growth regulatory circuit critical for mesenchymal glioblastoma survival. *Oncotarget*, **2017**, 8, 32977-32989	3.3	33
252	Pediatric gliomas as neurodevelopmental disorders. *Glia*, **2016**, 64, 879-95	9	32
251	F11R is a novel monocyte prognostic biomarker for malignant glioma. *PLoS ONE*, **2013**, 8, e77571	3.7	32

250	Cerebrospinal fluid proteomic analysis reveals dysregulation of methionine aminopeptidase-2 expression in human and mouse neurofibromatosis 1-associated glioma. *Cancer Research*, **2005**, 65, 9843-50	10.1	32
249	The NF2 interactor, hepatocyte growth factor-regulated tyrosine kinase substrate (HRS), associates with merlin in the "open" conformation and suppresses cell growth and motility. *Human Molecular Genetics*, **2001**, 10, 825-34	5.6	32
248	Dissecting Clinical Heterogeneity in Neurofibromatosis Type 1. *Annual Review of Pathology: Mechanisms of Disease*, **2017**, 12, 53-74	34	31
247	Evaluation of participant recruitment methods to a rare disease online registry. *American Journal of Medical Genetics, Part A*, **2014**, 164A, 1686-94	2.5	31
246	Protein 4.1B/differentially expressed in adenocarcinoma of the lung-1 functions as a growth suppressor in meningioma cells by activating Rac1-dependent c-Jun-NH(2)-kinase signaling. *Cancer Research*, **2006**, 66, 5295-303	10.1	31
245	Juvenile xanthogranuloma, neurofibromatosis 1, and juvenile chronic myeloid leukemia. *Archives of Dermatology*, **1996**, 132, 1390-1		31
244	Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties. *Cell Reports*, **2015**, 10, 1899-912	10.6	30
243	PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice. *Experimental Neurology*, **2011**, 232, 333-8	5.7	30
242	Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes. *Molecular Cancer Therapeutics*, **2011**, 10, 279-91	6.1	30
241	Expression of the tuberous sclerosis 2 gene product, tuberin, in adult and developing nervous system tissues. *Neurobiology of Disease*, **1996**, 3, 111-20	7.5	30
240	Neurofibromatosis-1 regulation of neural stem cell proliferation and multilineage differentiation operates through distinct RAS effector pathways. *Genes and Development*, **2015**, 29, 1677-82	12.6	29
239	Proteomic analysis reveals GIT1 as a novel mTOR complex component critical for mediating astrocyte survival. *Genes and Development*, **2016**, 30, 1383-8	12.6	29
238	Ku80 functions as a tumor suppressor in hepatocellular carcinoma by inducing S-phase arrest through a p53-dependent pathway. *Carcinogenesis*, **2012**, 33, 538-47	4.6	29
237	Acute presentation of a neurogenic sarcoma in a patient with neurofibromatosis type 1: a pathological and molecular explanation. Case report. *Journal of Neurosurgery*, **1996**, 84, 867-73	3.2	29
236	Expression profiling identifies a molecular signature of reactive astrocytes stimulated by cyclic AMP or proinflammatory cytokines. *Experimental Neurology*, **2008**, 210, 261-7	5.7	29
235	Functional significance of S6K overexpression in meningioma progression. *Annals of Neurology*, **2004**, 56, 295-8	9.4	29
234	Athymic mice reveal a requirement for T-cell-microglia interactions in establishing a microenvironment supportive of low-grade glioma growth. *Genes and Development*, **2018**, 32, 491-496	12.6	28
233	Gender as a disease modifier in neurofibromatosis type 1 optic pathway glioma. *Annals of Neurology*, **2014**, 75, 799-800	9.4	28

232	Comparative characterization of the human and mouse third ventricle germinal zones. *Journal of Neuropathology and Experimental Neurology*, **2011**, 70, 622-33	3.1	27
231	Tslc1 (nectin-like molecule-2) is essential for spermatozoa motility and male fertility. *Journal of Andrology*, **2006**, 27, 816-25		27
230	Membrane localization of the U2 domain of Protein 4.1B is necessary and sufficient for meningioma growth suppression. *Oncogene*, **2005**, 24, 1946-57	9.2	27
229	Overexpression of bax in human glioma cell lines. *Journal of Neurosurgery*, **1999**, 91, 483-9	3.2	27
228	Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1. *Communications Biology*, **2018**, 1, 158	6.7	27
227	RNA-sequencing reveals oligodendrocyte and neuronal transcripts in microglia relevant to central nervous system disease. *Glia*, **2015**, 63, 531-548	9	26
226	BRAFV600E mutation in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors. *Neuro-Oncology*, **2014**, 16, 466-7	1	26
225	Glomus tumors in individuals with neurofibromatosis type 1. *Journal of the American Academy of Dermatology*, **2014**, 71, 44-8	4.5	26
224	Ultrastructural characterization of the optic pathway in a mouse model of neurofibromatosis-1 optic glioma. *Neuroscience*, **2010**, 170, 178-88	3.9	26
223	Advances in neurofibromatosis 2 (NF2): a workshop report. *Journal of Neurogenetics*, **2000**, 14, 63-106	1.6	26
222	Neurofibromatosis 2. *Current Opinion in Neurology*, **2003**, 16, 27-33	7.1	26
221	Development of an international internet-based neurofibromatosis Type 1 patient registry. *Contemporary Clinical Trials*, **2013**, 34, 305-11	2.3	25
220	Assessment of pain and itch behavior in a mouse model of neurofibromatosis type 1. *Journal of Pain*, **2013**, 14, 628-37	5.2	25
219	Reduced activity of CD13/aminopeptidase N (APN) in aggressive meningiomas is associated with increased levels of SPARC. *Brain Pathology*, **2010**, 20, 200-10	6	25
218	Akt-dependent cell size regulation by the adhesion molecule on glia occurs independently of phosphatidylinositol 3-kinase and Rheb signaling. *Molecular and Cellular Biology*, **2005**, 25, 3151-62	4.8	25
217	A review of astrocytoma models. *Neurosurgical Focus*, **2000**, 8, 1-8	4.2	25
216	Spatially- and temporally-controlled postnatal p53 knockdown cooperates with embryonic Schwann cell precursor Nf1 gene loss to promote malignant peripheral nerve sheath tumor formation. *Oncotarget*, **2016**, 7, 7403-14	3.3	25
215	Fatty acid synthase as a novel target for meningioma therapy. *Neuro-Oncology*, **2010**, 12, 844-54	1	24

214	Using neurofibromatosis-1 to better understand and treat pediatric low-grade glioma. *Journal of Child Neurology*, **2008**, 23, 1186-94	2.5	24
213	Aberrant G protein signaling in nervous system tumors. *Journal of Neurosurgery*, **2002**, 97, 627-42	3.2	24
212	Neurofibromatosis type 1. Beyond positional cloning. *Archives of Neurology*, **1993**, 50, 1185-93		24
211	Complicated hereditary spastic paraparesis with cerebral white matter lesions. *American Journal of Medical Genetics Part A*, **1990**, 36, 251-7		24
210	How Support of Early Career Researchers Can Reset Science in the Post-COVID19 World. *Cell*, **2020**, 181, 1445-1449	56.2	23
209	Optic nerve tortuosity in children with neurofibromatosis type 1. *Pediatric Radiology*, **2013**, 43, 1336-43	2.8	23
208	Postoperative imaging surveillance in pediatric pilocytic astrocytomas. *Journal of Neurosurgery: Pediatrics*, **2010**, 6, 346-52	2.1	23
207	Developmental delays in children with neurofibromatosis type 1. *Journal of Child Neurology*, **2012**, 27, 641-4	2.5	23
206	Detection and measurement of neurofibromatosis-1 mouse optic glioma in vivo. *NeuroImage*, **2007**, 35, 1434-7	7.9	23
205	Meningothelial hyperplasia: a detailed clinicopathologic, immunohistochemical and genetic study of 11 cases. *Brain Pathology*, **2005**, 15, 109-15	6	23
204	Mlh1 deficiency accelerates myeloid leukemogenesis in neurofibromatosis 1 (Nf1) heterozygous mice. *Oncogene*, **2003**, 22, 4581-5	9.2	23
203	Glioneuronal tumours in neurofibromatosis type 1: MRI-pathological study. *Journal of Clinical Neuroscience*, **2004**, 11, 745-7	2.2	23
202	Midkine activation of CD8 T cells establishes a neuron-immune-cancer axis responsible for low-grade glioma growth. *Nature Communications*, **2020**, 11, 2177	17.4	22
201	The Learning Disabilities Network (LeaDNet): using neurofibromatosis type 1 (NF1) as a paradigm for translational research. *American Journal of Medical Genetics, Part A*, **2012**, 158A, 2225-32	2.5	22
200	Antiangiogenic agents for nonmalignant brain tumors. *Journal of Neurological Surgery, Part B: Skull Base*, **2013**, 74, 136-41	1.5	22
199	Height assessments in children with neurofibromatosis type 1. *Journal of Child Neurology*, **2013**, 28, 303-7	1.5	22
198	Functional analysis of the relationship between the neurofibromatosis 2 tumor suppressor and its binding partner, hepatocyte growth factor-regulated tyrosine kinase substrate. *Human Molecular Genetics*, **2002**, 11, 3167-78	5.6	22
197	A Novel Rac1-GSPT1 Signaling Pathway Controls Astrogliosis Following Central Nervous System Injury. *Journal of Biological Chemistry*, **2017**, 292, 1240-1250	5.4	21

196	Racial/Ethnic Differences in Pediatric Brain Tumor Diagnoses in Patients with Neurofibromatosis Type 1. *Journal of Pediatrics*, **2015**, 167, 613-20.e1-2	3.6	21
195	Implications of new understandings of gliomas in children and adults with NF1: report of a consensus conference. *Neuro-Oncology*, **2020**, 22, 773-784	1	21
194	Human iPSC-Derived Neurons and Cerebral Organoids Establish Differential Effects of Germline NF1 Gene Mutations. *Stem Cell Reports*, **2020**, 14, 541-550	8	21
193	Characterization of early communicative behavior in mouse models of neurofibromatosis type 1. *Autism Research*, **2018**, 11, 44-58	5.1	21
192	Clinical genomic profiling identifies TYK2 mutation and overexpression in patients with neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. *Cancer*, **2017**, 123, 1194-1201	6.4	21
191	Astrocyte-specific expression of CDK4 is not sufficient for tumor formation, but cooperates with p53 heterozygosity to provide a growth advantage for astrocytes in vivo. *Oncogene*, **2002**, 21, 1325-34	9.2	21
190	Role of the Rap1 GTPase in astrocyte growth regulation. *Glia*, **2003**, 42, 225-34	9	21
189	Molecular analysis of malignant triton tumors. *Human Pathology*, **1999**, 30, 984-8	3.7	21
188	Expression of the neurofibromatosis 1 (NF1) gene in reactive astrocytes in vitro. *NeuroReport*, **1995**, 6, 1565-8	1.7	21
187	Distribution and Within-Family Specificity of Quantitative Autistic Traits in Patients with Neurofibromatosis Type I. *Journal of Pediatrics*, **2015**, 167, 621-6.e1	3.6	20
186	A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study. *Neuro-Oncology*, **2020**, 22, 1527-1535	1	20
185	A Conserved Circadian Function for the Neurofibromatosis 1 Gene. *Cell Reports*, **2018**, 22, 3416-3426	10.6	20
184	Longitudinal analysis of developmental delays in children with neurofibromatosis type 1. *Journal of Child Neurology*, **2013**, 28, 1689-93	2.5	20
183	Regulation of mixed lineage kinase 3 is required for Neurofibromatosis-2-mediated growth suppression in human cancer. *Oncogene*, **2011**, 30, 781-9	9.2	20
182	HRS inhibits EGF receptor signaling in the RT4 rat schwannoma cell line. *Biochemical and Biophysical Research Communications*, **2005**, 335, 385-92	3.4	20
181	A genotype-phenotype correlation for quantitative autistic trait burden in neurofibromatosis 1. *Neurology*, **2018**, 90, 377-379	6.5	19
180	Tenascin C regulates multiple microglial functions involving TLR4 signaling and HDAC1. *Brain, Behavior, and Immunity*, **2019**, 81, 470-483	16.6	19
179	Activated k-ras, but not h-ras or N-ras, regulates brain neural stem cell proliferation in a raf/rb-dependent manner. *Stem Cells*, **2015**, 33, 1998-2010	5.8	19

178	Expression of the tumor suppressor genes NF2, 4.1B, and TSLC1 in canine meningiomas. *Veterinary Pathology*, **2009**, 46, 884-92	2.8	19
177	Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial. *Nature Medicine*, **2021**, 27, 165-173	50.5	19
176	Postnatal reduction of tuberous sclerosis complex 1 expression in astrocytes and neurons causes seizures in an age-dependent manner. *Epilepsia*, **2017**, 58, 2053-2063	6.4	18
175	Cognitive and behavioral problems in children with neurofibromatosis type 1: challenges and future directions. *Expert Review of Neurotherapeutics*, **2014**, 14, 1139-52	4.3	18
174	NG2-cells are not the cell of origin for murine neurofibromatosis-1 (Nf1) optic glioma. *Oncogene*, **2014**, 33, 289-99	9.2	18
173	Identification of transcriptional regulatory networks specific to pilocytic astrocytoma. *BMC Medical Genomics*, **2011**, 4, 57	3.7	18
172	Ammonium acetate protocol for the preparation of plasmid DNA suitable for mammalian cell transfections. *BioTechniques*, **1997**, 23, 424-7	2.5	18
171	Mouse models of tuberous sclerosis complex. *Journal of Child Neurology*, **2004**, 19, 726-33	2.5	18
170	Mouse glioma gene expression profiling identifies novel human glioma-associated genes. *Annals of Neurology*, **2002**, 51, 393-405	9.4	18
169	Loss of heterozygosity for the NF2 gene in retinal and optic nerve lesions of patients with neurofibromatosis 2. *Journal of Pathology*, **2002**, 198, 14-20	9.4	18
168	Merlin: hanging tumor suppression on the Rac. *Trends in Cell Biology*, **2001**, 11, 442-4	18.3	18
167	Expression of the neurofibromatosis type 1 (NF1) gene during mouse embryonic development. *Progress in Brain Research*, **1995**, 105, 327-35	2.9	18
166	Neurofibromatosis type 1 and optic pathway glioma: Molecular interplay and therapeutic insights. *Pediatric Blood and Cancer*, **2018**, 65, e26838	3	17
165	Novel BRAF Alteration in a Sporadic Pilocytic Astrocytoma. *Case Reports in Medicine*, **2012**, 2012, 418672	0.7	17
164	Colocalized cellular schwannoma and plexiform neurofibroma in the absence of neurofibromatosis. Case report. *Journal of Neurosurgery*, **2007**, 107, 435-9	3.2	17
163	Protein 4.1B expression is induced in mammary epithelial cells during pregnancy and regulates their proliferation. *Oncogene*, **2005**, 24, 6502-15	9.2	17
162	Defining the temporal course of murine neurofibromatosis-1 optic gliomagenesis reveals a therapeutic window to attenuate retinal dysfunction. *Neuro-Oncology*, **2017**, 19, 808-819	1	17
161	Children with 5Œend gene mutations are more likely to have glioma. *Neurology: Genetics*, **2017**, 3, e192	3.8	16

160	Human stem cell modeling in neurofibromatosis type 1 (NF1). *Experimental Neurology*, **2018**, 299, 270-280	3.7	16
159	Expression and function of somatostatin receptors in peripheral nerve sheath tumors. *Journal of Neuropathology and Experimental Neurology*, **2005**, 64, 1080-8	3.1	16
158	Whole tumor RNA-sequencing and deconvolution reveal a clinically-prognostic PTEN/PI3K-regulated glioma transcriptional signature. *Oncotarget*, **2017**, 8, 52474-52487	3.3	16
157	Mice with missense and nonsense NF1 mutations display divergent phenotypes compared with human neurofibromatosis type I. *DMM Disease Models and Mechanisms*, **2016**, 9, 759-67	4.1	16
156	Cognition, ADHD Symptoms, and Functional Impairment in Children and Adolescents With Neurofibromatosis Type 1. *Journal of Attention Disorders*, **2021**, 25, 1177-1186	3.7	16
155	Increased prevalence of brain tumors classified as T2 hyperintensities in neurofibromatosis 1. *Neurology: Clinical Practice*, **2018**, 8, 283-291	1.7	15
154	Neurofibromatosis type 1 and chronic neurological conditions in the United States: an administrative claims analysis. *Genetics in Medicine*, **2015**, 17, 36-42	8.1	15
153	Brainstem glioma presenting as pruritus in children with neurofibromatosis-1. *Journal of Pediatric Hematology/Oncology*, **2009**, 31, 972-6	1.2	15
152	Disruption of 14-3-3 binding does not impair Protein 4.1B growth suppression. *Oncogene*, **2004**, 23, 3589-96	9.2	15
151	Neurofibromin in the brain. *Journal of Child Neurology*, **2002**, 17, 592-601; discussion 602-4, 646-51	2.5	15
150	ABCG1 maintains high-grade glioma survival in vitro and in vivo. *Oncotarget*, **2016**, 7, 23416-24	3.3	15
149	KIAA1549-BRAF Expression Establishes a Permissive Tumor Microenvironment Through NFB-Mediated CCL2 Production. *Neoplasia*, **2019**, 21, 52-60	6.4	15
148	The impact of coexisting genetic mutations on murine optic glioma biology. *Neuro-Oncology*, **2015**, 17, 670-7	1	14
147	3-D imaging mass spectrometry of protein distributions in mouse Neurofibromatosis 1 (NF1)-associated optic glioma. *Journal of Proteomics*, **2016**, 149, 77-84	3.9	14
146	Eliminating barriers to personalized medicine: learning from neurofibromatosis type 1. *Neurology*, **2014**, 83, 463-71	6.5	14
145	Motivational disturbances and effects of L-dopa administration in neurofibromatosis-1 model mice. *PLoS ONE*, **2013**, 8, e66024	3.7	14
144	The ecology of brain tumors: lessons learned from neurofibromatosis-1. *Oncogene*, **2011**, 30, 1135-46	9.2	14
143	Genetic heterogeneity of stably transfected cell lines revealed by expression profiling with oligonucleotide microarrays. *Journal of Cellular Biochemistry*, **2003**, 90, 1068-78	4.7	14

142	Molecular biology of Duchenne and Becker muscular dystrophy: clinical applications. *Annals of Neurology*, **1989**, 26, 189-94	9.4	14
141	Neurofibromatosis 2 tumor suppressor protein, merlin, forms two functionally important intramolecular associations. *Journal of Neuroscience Research*, **1999**, 58, 706-16	4.4	14
140	Neurofibromatosis 2 in children presenting during the first decade of life. *Neurology*, **2019**, 93, e964-e967	7.5	13
139	CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice. *Journal of Neuroimmunology*, **2010**, 224, 108-13	3.5	13
138	Parallels between tuberous sclerosis complex and neurofibromatosis 1: common threads in the same tapestry. *Seminars in Pediatric Neurology*, **1998**, 5, 276-86	2.9	13
137	Transfection of C6 glioma cells with the bax gene and increased sensitivity to treatment with cytosine arabinoside. *Journal of Neurosurgery*, **1998**, 88, 99-105	3.2	13
136	Characterization and expression of H-21 region gene products on bone marrow-derived macrophages. *European Journal of Immunology*, **1982**, 12, 991-7	6.1	13
135	The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation. *Oncotarget*, **2017**, 8, 47206-47215	3.3	13
134	Junctional Adhesion Molecules in Cancer: A Paradigm for the Diverse Functions of Cell-Cell Interactions in Tumor Progression. *Cancer Research*, **2020**, 80, 4878-4885	10.1	13
133	NF1 mutation drives neuronal´activity-dependent initiation of optic glioma. *Nature*, **2021**, 594, 277-282	50.4	13
132	Brain tumors in Neurofibromatosis type 1. *Neuro-Oncology Advances*, **2019**, 1, vdz040	0.9	12
131	A neuropsychological perspective on attention problems in neurofibromatosis type 1. *Journal of Attention Disorders*, **2013**, 17, 489-96	3.7	12
130	Updated nomenclature for human and mouse neurofibromatosis type 1 genes. *Neurology: Genetics*, **2017**, 3, e169	3.8	12
129	Validity of participant-reported diagnoses in an online patient registry: a report from the NF1 Patient Registry Initiative. *Contemporary Clinical Trials*, **2015**, 40, 212-7	2.3	12
128	Conditional KIAA1549:BRAF mice reveal brain region- and cell type-specific effects. *Genesis*, **2013**, 51, 708-16	1.9	12
127	Cancer stem cells and brain tumors: uprooting the bad seeds. *Expert Review of Anticancer Therapy*, **2007**, 7, 1581-90	3.5	12
126	Cerebral vasculopathy and infarction in a woman with carcinomatous meningitis. *Journal of Neuro-Oncology*, **1990**, 9, 183-5	4.8	12
125	Clearing the Fog surrounding Chemobrain. *Cell*, **2019**, 176, 2-4	56.2	12

124	Increased Tissue Stiffness in Tumors from Mice with Neurofibromatosis-1 Optic Glioma. *Biophysical Journal*, **2017**, 112, 1535-1538	2.9	11
123	Parental age and Neurofibromatosis Type 1: a report from the NF1 Patient Registry Initiative. *Familial Cancer*, **2015**, 14, 317-24	3	11
122	Update from the 2013 International Neurofibromatosis Conference. *American Journal of Medical Genetics, Part A*, **2014**, 164A, 2969-78	2.5	11
121	Improving outcomes for neurofibromatosis 1-associated brain tumors. *Expert Review of Anticancer Therapy*, **2015**, 15, 415-23	3.5	11
120	Defining future directions in spinal cord tumor research: proceedings from the National Institutes of Health workshop. *Journal of Neurosurgery: Spine*, **2010**, 12, 117-21	2.8	11
119	New insights into the neurofibromatoses. *Current Opinion in Neurology*, **1994**, 7, 166-71	7.1	11
118	Magnetic resonance imaging of ataxic hemiparesis localized to the corona radiata. *Stroke*, **1989**, 20, 1571-3	6.7	11
117	Loss of TDP-43 in astrocytes leads to motor deficits by triggering A1-like reactive phenotype and triglial dysfunction. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 29101-29112	11.5	11
116	Reproducibility of cognitive endpoints in clinical trials: lessons from neurofibromatosis type 1. *Annals of Clinical and Translational Neurology*, **2019**, 6, 2555-2565	5.3	11
115	Humanized neurofibroma model from induced pluripotent stem cells delineates tumor pathogenesis and developmental origins. *Journal of Clinical Investigation*, **2021**, 131,	15.9	11
114	Adaptive functioning in children with neurofibromatosis type 1: relationship to cognition, behavior, and magnetic resonance imaging. *Developmental Medicine and Child Neurology*, **2019**, 61, 972-978	3.3	10
113	Piebaldism and neurofibromatosis type 1: horses of very different colors. *Journal of Investigative Dermatology*, **2004**, 122, xxxiv-xxxv	4.3	10
112	Diethylstilbestrol effects and lymphomagenesis in Mlh1-deficient mice. *International Journal of Cancer*, **2005**, 115, 666-9	7.5	10
111	Comments on neurofibromatosis 1 and optic pathway tumors. *American Journal of Medical Genetics Part A*, **2001**, 102, 105		10
110	Expression of the neurofibromatosis 1 (NF1) gene during growth arrest. *NeuroReport*, **1996**, 7, 601-4	1.7	9
109	Transglutaminase 2 expression is increased as a function of malignancy grade and negatively regulates cell growth in meningioma. *PLoS ONE*, **2014**, 9, e108228	3.7	9
108	Neurofibroma and cellular neurofibroma with atypia: a report of 14 tumors. *American Journal of Surgical Pathology*, **1999**, 23, 1156-8	6.7	9
107	Insights into optic pathway glioma vision loss from mouse models of neurofibromatosis type 1. *Journal of Neuroscience Research*, **2019**, 97, 45-56	4.4	9

106	Integrated molecular and clinical analysis of low-grade gliomas in children with neurofibromatosis type 1 (NF1). *Acta Neuropathologica*, **2021**, 141, 605-617	14.3	9
105	Patient-derived iPSC-cerebral organoid modeling of the 17q11.2 microdeletion syndrome establishes CRLF3 as a critical regulator of neurogenesis. *Cell Reports*, **2021**, 36, 109315	10.6	9
104	Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner. *PLoS ONE*, **2014**, 9, e97320	3.7	8
103	Reply: To PMID 24375753. *Annals of Neurology*, **2014**, 75, 800-1	9.4	8
102	All in the family: using inherited cancer syndromes to understand de-regulated cell signaling in brain tumors. *Journal of Cellular Biochemistry*, **2007**, 102, 811-9	4.7	8
101	Generation of a reporter mouse line expressing Akt and EGFP upon Cre-mediated recombination. *Genesis*, **2008**, 46, 256-64	1.9	8
100	Congenital nystagmus in a (46,XX/45,X) mosaic woman from a family with X-linked congenital nystagmus. *American Journal of Medical Genetics Part A*, **1991**, 39, 167-9		8
99	In-vitro-derived bone marrow macrophages. Expression of Ia antigens during macrophage differentiation. *Transplantation*, **1984**, 37, 585-90	1.8	8
98	Associations between allergic conditions and pediatric brain tumors in Neurofibromatosis type 1. *Familial Cancer*, **2016**, 15, 301-8	3	7
97	NF1 glioblastoma clonal profiling reveals mutations as potential somatic oncogenic events. *Neurology*, **2019**, 93, 1067-1069	6.5	7
96	The 43000 growth-associated protein functions as a negative growth regulator in glioma. *Cancer Research*, **2003**, 63, 2933-9	10.1	7
95	Contextual signaling in cancer. *Seminars in Cell and Developmental Biology*, **2016**, 58, 118-26	7.5	6
94	Pain symptomology, functional impact, and treatment of people with Neurofibromatosis type 1. *Journal of Pain Research*, **2019**, 12, 2555-2561	2.9	6
93	The power of the few. *Genes and Development*, **2017**, 31, 1177-1179	12.6	6
92	Parent-of-origin in individuals with familial neurofibromatosis type 1 and optic pathway gliomas. *Familial Cancer*, **2012**, 11, 653-6	3	6
91	Report from the fifth National Cancer Institute Mouse Models of Human Cancers Consortium Nervous System Tumors Workshop. *Neuro-Oncology*, **2011**, 13, 692-9	1	6
90	Tumor suppressor gene regulation of cell growth: recent insights into neurofibromatosis 1 and 2 gene function. *Cell Biochemistry and Biophysics*, **2001**, 34, 61-78	3.2	6
89	Pseudocervical cord syndrome: a deceptive flumazenil reversible manifestation of hepatic encephalopathy. *Archives of Neurology*, **1996**, 53, 956		6

88	Chromosome 11q23.3-qter deletion and Alexander disease. *American Journal of Medical Genetics Part A*, **1991**, 39, 226-7		6
87	KIR2DL5 mutation and loss underlies sporadic dermal neurofibroma pathogenesis and growth. *Oncotarget*, **2017**, 8, 47574-47585	3.3	6
86	Challenges in Drug Discovery for Neurofibromatosis Type 1-Associated Low-Grade Glioma. *Frontiers in Oncology*, **2016**, 6, 259	5.3	6
85	Variability of Betweenness Centrality and Its Effect on Identifying Essential Genes. *Bulletin of Mathematical Biology*, **2019**, 81, 3655-3673	2.1	5
84	Nonoptic pathway tumors in children with neurofibromatosis type 1. *Neurology*, **2020**, 95, e1052-e1059	6.5	5
83	II-spectrin immunohistochemistry as a potential diagnostic tool with high sensitivity for malignant peripheral nerve sheath tumors. *Neuro-Oncology*, **2018**, 20, 858-860	1	5
82	The management of neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors: challenges, progress, and future prospects. *Expert Opinion on Orphan Drugs*, **2017**, 5, 623-631	1.1	5
81	Visual function and optic pathway glioma: a critical response. *JAMA Ophthalmology*, **2013**, 131, 120-1	3.9	5
80	Lack of NF1 expression in a sporadic schwannoma from a patient without neurofibromatosis. *Journal of Neuro-Oncology*, **1995**, 25, 103-11	4.8	5
79	Symptomatic hydrocephalus and reversible spinal cord compression in Listeria monocytogenes meningitis. Case report. *Journal of Neurosurgery*, **1989**, 71, 620-2	3.2	5
78	Personality changes associated with thalamic infiltration. *Journal of Neuro-Oncology*, **1990**, 8, 263-7	4.8	5
77	Lipid composition and in vitro biosynthetic rates of neutral lipids and phosphatidylcholine in anterior and posterior chambers of the goldfish swimbladder. *Comparative Biochemistry and Physiology A, Comparative Physiology*, **1981**, 69, 291-295		5
76	Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma. *PLoS ONE*, **2018**, 13, e0190001	3.7	5
75	Using Epigenetic Reprogramming to Treat Pediatric Brain Cancer. *Cancer Cell*, **2017**, 31, 609-611	24.3	4
74	Commentary: Identification of Mutation Regions on Responsible for High- and Low-Risk Development of Optic Pathway Glioma in Neurofibromatosis Type I. *Frontiers in Genetics*, **2019**, 10, 115	4.5	4
73	Height Growth Impairment in Children With Neurofibromatosis Type 1 Is Characterized by Decreased Pubertal Growth Velocity in Both Sexes. *Journal of Child Neurology*, **2018**, 33, 762-766	2.5	4
72	Review: low-grade gliomas as neurodevelopmental disorders: insights from mouse models of neurofibromatosis-1. *Neuropathology and Applied Neurobiology*, **2012**, 38, 241-53	5.2	4
71	Genome-wide polymorphism analysis demonstrates a monoclonal origin of pilocytic astrocytoma. *Neuropathology and Applied Neurobiology*, **2011**, 37, 321-5	5.2	4

70	Rethinking pediatric gliomas as developmental brain abnormalities. *Current Topics in Developmental Biology*, **2011**, 94, 283-308	5.3	4
69	An alternative apnea test for the evaluation of brain death. *Annals of Neurology*, **1991**, 30, 852-3	9.4	4
68	The Psychoimmune System in Later Life **1998**, 281-295		4
67	Gliosarcomas lack BRAF mutation, but a subset exhibit β-catenin nuclear localization. *Neuropathology*, **2016**, 36, 448-455	2	4
66	Neurofibromatosis type 1 (Nf1)-mutant mice exhibit increased sleep fragmentation. *Journal of Sleep Research*, **2019**, 28, e12816	5.8	4
65	Temporal, spatial, and genetic constraints contribute to the patterning and penetrance of murine neurofibromatosis-1 optic glioma. *Neuro-Oncology*, **2021**, 23, 625-637	1	4
64	A pilot study for evaluation of hypotonia in children with neurofibromatosis type 1. *Journal of Child Neurology*, **2015**, 30, 382-5	2.5	3
63	Defining the Research Landscape for Dermal Neurofibromas. *Oncology Times*, **2016**, 38, 14-15	3.5	3
62	NF GEMMs already! The power and promise of mouse tumor models. *Cancer Cell*, **2014**, 26, 596-9	24.3	3
61	The Tropism of Pleiotrophin: Orchestrating Glioma Brain Invasion. *Cell*, **2017**, 170, 821-822	56.2	3
60	In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila. *PLoS ONE*, **2014**, 9, e90853	3.7	3
59	The taxonomy of brain cancer stem cells: what's in a name?. *Oncoscience*, **2014**, 1, 241-7	0.8	3
58	The association between hypotonia and brain tumors in children with neurofibromatosis type 1. *Journal of Child Neurology*, **2013**, 28, 1664-7	2.5	3
57	Mice with GFAP-targeted loss of neurofibromin demonstrate increased axonal MET expression with aging. *Glia*, **2007**, 55, 723-33	9	3
56	Major histocompatibility complex regulation of the immune response. *Journal of Surgical Research*, **1985**, 39, 172-81	2.5	3
55	BRAF mutations may identify a clinically distinct subset of glioblastoma. *Scientific Reports*, **2021**, 11, 19999	4.9	3
54	Neurofibromatosis 1 - Mutant microglia exhibit sexually-dimorphic cyclic AMP-dependent purinergic defects. *Neurobiology of Disease*, **2020**, 144, 105030	7.5	3
53	Reimagining pilocytic astrocytomas in the context of pediatric low-grade gliomas. *Neuro-Oncology*, **2021**, 23, 1634-1646	1	3

52	Peri-gestational risk factors for pediatric brain tumors in Neurofibromatosis Type 1. *Cancer Epidemiology*, **2016**, 42, 53-9	2.8	3
51	Visual outcomes following everolimus targeted therapy for neurofibromatosis type 1-associated optic pathway gliomas in children. *Pediatric Blood and Cancer*, **2021**, 68, e28833	3	3
50	The Sociobiology of Brain Tumors. *Advances in Experimental Medicine and Biology*, **2020**, 1225, 115-125	3.6	2
49	Macrocephaly Is Not a Predictor of Optic Pathway Glioma Development or Treatment in Neurofibromatosis Type 1. *Journal of Child Neurology*, **2016**, 31, 1540-1545	2.5	2
48	Independent mutations underlie caf□au-lait macule development in a woman with segmental NF1. *Neurology: Genetics*, **2018**, 4, e261	3.8	2
47	Neurofibromatosis and other genetic syndromes. *Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn*, **2012**, 105, 569-82	3	2
46	Modeling human brain tumors in mice. *Brain Pathology*, **2009**, 19, 108-11	6	2
45	Rap1 activity is elevated in malignant astrocytomas independent of tuberous sclerosis complex-2 gene expression **2003**, 22, 195		2
44	Neurofibromatosis type 1 **2004**, 42-49		2
43	762 Overexpression of EGFRvIII Potentiates the Development and Aggressiveness of Astrocytomas in an Activated Ras Transgenic Mouse Astrocytoma Model. *Neurosurgery*, **2001**, 49, 525	3.2	2
42	Regulated temporal-spatial astrocyte precursor cell proliferation involves BRAF signalling in mammalian spinal cord.. *Journal of Cell Science*, **2012**, 125, e1-e1	5.3	2
41	Familial Lipomas Without Classic Neurofibromatosis-1 Caused by a Missense Germline NF1 Mutation. *Neurology: Genetics*, **2021**, 7, e582	3.8	2
40	Autism in neurofibromatosis type 1: misuse of covariance to dismiss autistic trait burden. *Developmental Medicine and Child Neurology*, **2021**, 63, 233-234	3.3	2
39	Understanding a complicated Gal-1. *Neuro-Oncology*, **2019**, 21, 1341-1343	1	1
38	Neurofibromatoses **2015**, 921-933		1
37	A multidisciplinary approach in neurofibromatosis 1--authorsOreply. *Lancet Neurology, The*, **2015**, 14, 30-1	24.1	1
36	Teaching NeuroImages: T2 hyperintensities in neurofibromatosis type 1. *Neurology*, **2013**, 80, e215-6	6.5	1
35	Molecular genetics of optic glioma: lessons learned from neurofibromatosis-1 genetically engineered mice. *Expert Review of Ophthalmology*, **2011**, 6, 363-369	1.5	1

34	NF1-Associated Optic Glioma **2012**, 341-352		1
33	Characterization of three new intra-I region recombinant mouse strains, B10.ASR7 (H-2as3), B10.BAR4 (H-2h6), and B10.BASR1 (H-2as4). *Immunogenetics*, **1984**, 19, 175-8	3.2	1
32	Neurofibromatosis type 1 **2006**, 903-915		1
31	Visual field outcomes in children treated for neurofibromatosis type 1-associated optic pathway gliomas: a multicenter retrospective study. *Journal of AAPOS*, **2020**, 24, 349.e1-349.e5	1.3	1
30	Shared developmental gait disruptions across two mouse models of neurodevelopmental disorders		1
29	Shared developmental gait disruptions across two mouse models of neurodevelopmental disorders. *Journal of Neurodevelopmental Disorders*, **2021**, 13, 10	4.6	1
28	RNA sequence analysis reveals ITGAL/CD11A as a stromal regulator of murine low-grade glioma growth. *Neuro-Oncology*, **2021**,	1	1
27	De novo development of gliomas in a child with neurofibromatosis type 1, fragile X and previously normal brain magnetic resonance imaging. *Radiology Case Reports*, **2016**, 11, 33-5	1	1
26	SRF Is Required for Maintenance of Astrocytes in Non-Reactive State in the Mammalian Brain. *ENeuro*, **2021**, 8,	3.9	1
25	Asthma reduces glioma formation by T cell decorin-mediated inhibition of microglia. *Nature Communications*, **2021**, 12, 7122	17.4	1
24	Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.. *Nature Communications*, **2022**, 13, 2785	17.4	1
23	Generation of human induced pluripotent stem cell-derived cerebral organoids for cellular and molecular characterization.. *STAR Protocols*, **2022**, 3, 101173	1.4	0
22	Neurofibromatosis type 1 **2020**, 185-200		0
21	Predictive Modeling for Clinical Features Associated With Neurofibromatosis Type 1.. *Neurology: Clinical Practice*, **2021**, 11, 497-505	1.7	0
20	Immune cell analysis of pilocytic astrocytomas reveals sexually dimorphic brain region-specific differences in T-cell content. *Neuro-Oncology Advances*, **2021**, 3, vdab068	0.9	0
19	Clinic-based study of plexiform neurofibromas in neurofibromatosis 1 **2000**, 92, 132		0
18	Immune deconvolution and temporal mapping identifies stromal targets and developmental intervals for abrogating murine low-grade optic glioma formation.. *Neuro-Oncology Advances*, **2022**, 4, vdab194	0.9	0
17	Reply to @ssembling the brain trust: the multidisciplinary imperative in neuro-oncologyO*Nature Reviews Clinical Oncology*, **2019**, 16, 522-523	19.4	

16	Caddyshack therapeutics: overcoming glioblastoma adaptation. *Neuro-Oncology*, **2017**, 19, 1429-1431	1
15	Neurofibromatosis type I679-685	
14	Using the neurofibromatosis tumor predisposition syndromes to understand normal nervous system development. *Scientifica*, **2014**, 2014, 915725	2.6
13	Using Genetically Engineered Mouse Models to Understand Low-Grade Glioma Development and Growth in Children. *Neuromethods*, **2012**, 203-215	0.4
12	The elders of the kibbutz. *International Journal of Aging and Human Development*, **2007**, 64, 47-65	1.8
11	Limitations of magnetic resonance spectroscopy in patients with white matter disease. *Annals of Neurology*, **1994**, 36, 932-3	9.4
10	Congenital nystagmus in a [46,XX/45,X] Mosaic woman from a damily with X-linked congenital nystagmus. *American Journal of Medical Genetics Part A*, **1992**, 43, 897-897	
9	Age and leadership: Cross-cultural observations. *Psychoanalytic Inquiry*, **1982**, 2, 109-120	0.2
8	Children with supratentorial midline pilocytic astrocytomas exhibit multiple progressions and acquisition of neurologic deficits over time.. *Neuro-Oncology Advances*, **2022**, 4, vdab187	0.9
7	Neurofibromatosis 1 and 2 **2006**, 1160-1164	
6	Human induced pluripotent stem cell modeling of neurofibromatosis type 1 **2022**, 1-30	
5	Neurofibromatosis 1 **2007**, 413-423	
4	Using Neurofibromatosis Type 1 Mouse Models to Understand Human Pediatric Low-Grade Gliomas **2009**, 45-59	
3	Pediatric Low-Grade Glioma: The Role of Neurofi bromatosis-1 in Guiding Therapy. *Pediatric Cancer*, **2012**, 285-294	
2	Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1. *Neuro-Oncology Advances*, **2020**, 2, i75-i84	0.9
1	LINC-08. Neuro-Oncology tumor board □bne-year experience of international collaboration. *Neuro-Oncology*, **2022**, 24, i163-i164	1